The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses-Reference-Cited by-同舟云学术

The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses

Author:

Anz D.¹²,Kruger S.¹,Haubner S.¹,Rapp M.¹,Bourquin C.³,Endres S.¹

Affiliation:

1. Division of Clinical Pharmacology; Center of Integrated Protein Science Munich (CIPS-M), Klinikum der Universität München; Munich Germany

2. Department of Gastroenterology Medizinische Klinik und Poliklinik IV; Klinikum der Universität München; Munich Germany

3. Chair of Pharmacology, Department of Medicine; University of Fribourg; Fribourg Switzerland

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

Reference12 articles.

3. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody;Fox;J Immunol,1984

5. 1 F7, a novel cell surface molecule, involved in helper function of CD4 cells;Morimoto;J Immunol,1989

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献